Medical care for people with obesity is changing rapidly. Body mass index, or BMI, was once considered the gold standard for diagnosis but has proven to be less accurate than once thought. Meanwhile, the advent of GLP-1 drugs has provided patients with treatment options that were unimaginable just a decade ago.
Dr. Fatima Cody Stanford, an obesity medicine physician, joins host Dr. Joel Bervell on a new episode of The Dose podcast to talk about the state of obesity care in the United States. Together, they explore why insurers are hesitant to cover medications like Ozempic, how BMI fails to catch real health risks, and what the future of obesity treatment looks like for patients and public health.
